Massachusetts Society of Clinical Oncologists - FDA Approved brentuximab vedotin (Adcetris) to treat previous untreated stage III and IV cHL

"The voice for cancer physicians and their patients in Massachusetts."

Home
Resources
FDA Approvals
FDA Approved brentuximab vedotin (Adcetris) to treat previous untreated stage III and IV cHL

FDA Approved brentuximab vedotin (Adcetris) to treat previous untreated stage III and IV cHL

29 Jun 2018 7:48 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved brentuximab vedotin (Adcentris; Seattle Genomics) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org